MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress

Experimental Neurology

Volumn 144, Issue 1, 1997, Pages 193-198

  Fallon, Jonathan ^a   Matthews, Russell T ^a   Hyman, Bradley T ^a   Beal, M Flint ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SPIN TRAPPING; SUBSTANTIA NIGRA;

EID: 0031105818     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6416     Document Type: Article

References (27)

1. + induced oxygen radical formation with mitochondrial enzymes. Free Radic. Biol. Med. 15: 181-186.
2. 2. Albin, R. L., and J. T. Greenamyre. 1992. Alternative excitotoxic hypotheses. Neurology 42: 733.
3. 3. Beal, M. F. 1992. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31: 119-130.
4. 4. Beal, M. F. 1995. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38: 357-366.
5. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 36: 882-888.
6. 6. Bloem, B. R., I. Irwin, O. J. S. Buruma, J. Haan, R. A. C. Roos, J. W. Tetrud, and J. W. Langsten. 1990. The MPTP model: Versatile contributions to the treatment of idiopathic Parkinson's disease. J. Neurol. Sci. 97: 273-293.
7. 7. Chan, P., L. E. DeLanney I. Irwin, J. W. Langsten, and D. DiMonte. 1991. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57: 348-351.
8. +) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat. Neurosci. Lett. 161: 121-123.
9. 9. Frim, D. M., T. A. Uhler, W. R. Galpern, M. F. Beal, X. O. Breakfield, and O. Isacson. 1994. Biologically delivered BDNF increases dopaminergic neuronal survival in a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 91: 5104-5108.
10. 10. Giovanni, A., B.-A. Sieber, R. E. Heikkila, and P. K. Sonsalla. 1991. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Ther. 257: 691-697.
11. 11. Hantraye, P., M. Varastet, M. Peschanski, D. Riche, P. Cesaro, J. C. Willer, and M. Maziere. 1993. Stable Parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53: 169-178.
12. +) induces NADH-dependent Superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170: 1049-1055.
13. + within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study. Neuroscience 40: 133-158.
14. 14. Huang, C-C., C.-S. Lu, N.-S. Chu, F. Hochberg, D. Lilienfeld, W. Olanow, and D. B. Calne. 1993. Progression after chronic manganese exposure. Neurology 43: 1479-1483.
15. 15. Kamada, K., K. Houkin, T. Aoki, M. Koiwa, T. Kashiwaba, Y. Iwasaki, and H. Abe. 1994. Cerebral metabolic changes in delayed carbon monoxide sequelae studied by proton MR spectroscopy. Neuroradiology 36: 104-106.
16. 16. Lee, M. S., and C. D. Marsden. 1994. Neurological sequelae following carbon monoxide poisoning clinical course and outcome according to the clinical types and brain computed tomography scan findings. Movement Disord. 9: 550-558.
17. 17. Przedborski, S., V. Kostic, V. Jackson-Lewis, A. B. Naini, S. Simonetti, S. Fahn, E. Carlson, C. J. Epstein, and J. L. Cadet. 1992. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12: 1658-1667.
18. +. Biochem. Biophys. Res. Commun. 189: 47-52.
19. + and MPTP-analogues in biological samples after purification over sephadex G10. Life Sci. 37: 1633-1640.
20. 20. Rosenow, F., K. Herholz, H. Lanfermann, G. Weuthen, R. Ebner, J. Kessler, M. Ghaemi, and W.-D. Heiss. 1995. Neurological sequelae of cyanide intoxication - The patterns of clinical, magnetic resonance imaging and positron emission tomography findings. Ann. Neurol. 38: 825-828.
21. 21. Sauer, H., and W. H. Oertel. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415.
22. 10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132: 279-283.
23. +) nigral toxicity in the rat by prior decortication or MK-801 treatment: A sterological estimate of neuronal loss. Neurobiol. Aging 14: 295-301.
24. 24. Storey, E., B. T. Hyman, B. Jenkins, E. Brouillet, J. M. Miller, B. R. Rosen, and M. F. Beal. 1992. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58: 1975-1978.
25. 25. Tipton, K. F., and T. P. Singer. 1993. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61: 1191-1206.
26. 26. Vingerhoets, F. J. G., B. J. Snow, C. S. Lee, M. Schulzer, E. Mak, and D. B. Calne. 1994. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism. Ann. Neurol. 36: 759-764.
27. 27. Vingerhoets, F. J. G., B. J. Snow, J. W. Tetrud, J. W. Langston, M. Schulzer, and D. B. Calne. 1994. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. 36: 765-770.